shRNA-Modified CD34 Cell Therapy

N/A

Report date: 2026/04/13 20:02:18

Base Information

Drug NameshRNA-Modified CD34 Cell Therapy

Drug Alias NameshRNA-modified CD34+ CellsShrna modified CD34 cells Kanglin-biotechKL-AI20

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapySmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > short hairpin RNA

Mechanisms of ActionCell replacementsHematopoietic progenitor cell antigen CD34 modulators

TargetsHematopoietic progenitor cell antigen CD34

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesKanglin Biotech (Hangzhou) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesKanglin Biotech (Hangzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsHIV Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A